Heine Hansen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Heine Hansen has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Bo Gronlund
Department of Oncology, Rigshospitalet, Copenhagen University Hospital, 9 Blegdamsvej, DK-2100 Copenhagen, Denmark
1 shared publication - Claus Høgdall
Department of Gynecology, Copenhagen University Hospital, Rigshospitalet, 2100 Copenhagen, Denmark
1 shared publication - Cristiana Sessa
Istituto Oncologico della Svizzera Italiana (IOSI), Ente Ospedaliero Cantonale (EOC), Via A. Gallino, 6500 Bellinzona, Switzerland
1 shared publication - Elizabeth A. Eisenhauer
Department of Oncology, Queen's University, Kingston, Ontario, Canada
1 shared publication - Fred R. Hirsch
Icahn School of Medicine at Mount Sinai, New York, NY
1 shared publication J. P. Neijt
Utrecht University Hospital Utrecht, The Netherlands
1 shared publication
Latest Publications
- Open Access
- 1 January 2024
- Published by Walter de Gruyter GmbH in Open Philosophy
- Vol. 7 (1)
Abelard’s Ontology of Forms: Some New Evidence from theNominalesand theAlbricani
This article concerns existents as a contentious issue in contemporary Abelardian scholarship. More precisely, it concerns the ontological standing of forms in Abelard’s metaphysics. Take, for example, the apple on my desk. What ontological standing does its redness have? Is it an actual entity over and above the apple or is it in some sense “reducible” to it? Abelard, famously, was a nominalist, so the question is not about some purported universal redness. Rather, it is about the particular redness of the particular apple on my desk. The issue is contentious in that the best current accounts of Abelard’s metaphysics disagree strongly about how to answer this question. Here, rather than focusing on Abelard’s own writings – which so far have yielded no definitive answer – I will consider some anonymously transmitted and mainly unedited logical texts from the twelfth century and show how his contemporaries understood Abelard’s view and how the followers of his philosophical nemesis, Alberic of Paris, reacted to it.
- 1 January 2024
- Published by Walter de Gruyter GmbH in Open Philosophy
- Vol. 7 (1)
Open AccessAbelard’s Ontology of Forms: Some New Evidence from theNominalesand theAlbricani
This article concerns existents as a contentious issue in contemporary Abelardian scholarship. More precisely, it concerns the ontological standing of forms in Abelard’s metaphysics. Take, for example, the apple on my desk. What ontological standing does its redness have? Is it an actual entity over and above the apple or is it in some sense “reducible” to it? Abelard, famously, was a nominalist, so the question is not about some purported universal redness. Rather, it is about the particular redness of the particular apple on my desk. The issue is contentious in that the best current accounts of Abelard’s metaphysics disagree strongly about how to answer this question. Here, rather than focusing on Abelard’s own writings – which so far have yielded no definitive answer – I will consider some anonymously transmitted and mainly unedited logical texts from the twelfth century and show how his contemporaries understood Abelard’s view and how the followers of his philosophical nemesis, Alberic of Paris, reacted to it.
- 17 August 2022
- Published by Walter de Gruyter GmbH in Vivarium
- Vol. 60 (2-3) , 113-136
Introduction: Special Issue on the Twelfth-Century Logical Schools
This special issue grew out of a small conference The Known & the Unknown: Exploring Twelfth-Century Philosophy, which was funded by the Carlsberg Foundation, hosted by the Saxo Institute, and held at the University of Copenhagen in April 2018. Its central topic was the many, mostly unexplored, commentaries on Aristotle, Boethius, and Porphyry that constitute the key textual evidence for a fascinating phenomenon that, although it played a pivotal role in the philosophical revival of Western Europe, remains frustratingly underexplored to this day: the logical schools of the twelfth century. The present introduction has two parts. In the first part, John Marenbon lays out the background to this special issue of Vivarium as a whole, explaining both what the philosophical project pursued by twelfth-century logicians was and how, and how far, the historical project of understanding it has progressed over the last two hundred years. In the second part, Heine Hansen briefly presents the issue and its contents.
- 17 August 2022
- Published by Walter de Gruyter GmbH in Vivarium
- Vol. 60 (2-3) , 113-136
Introduction: Special Issue on the Twelfth-Century Logical Schools
This special issue grew out of a small conference The Known & the Unknown: Exploring Twelfth-Century Philosophy, which was funded by the Carlsberg Foundation, hosted by the Saxo Institute, and held at the University of Copenhagen in April 2018. Its central topic was the many, mostly unexplored, commentaries on Aristotle, Boethius, and Porphyry that constitute the key textual evidence for a fascinating phenomenon that, although it played a pivotal role in the philosophical revival of Western Europe, remains frustratingly underexplored to this day: the logical schools of the twelfth century. The present introduction has two parts. In the first part, John Marenbon lays out the background to this special issue of Vivarium as a whole, explaining both what the philosophical project pursued by twelfth-century logicians was and how, and how far, the historical project of understanding it has progressed over the last two hundred years. In the second part, Heine Hansen briefly presents the issue and its contents.
- 17 August 2022
- Published by Walter de Gruyter GmbH in Vivarium
- Vol. 60 (2-3) , 248-270
This Woman Is a Father? The Albricani on a Puzzle about Relations
Medieval philosophers had a predilection for using the correlative pair father and son as an illustrative example in their discussions of relations. The use of this example has sometimes led to charges of confusion on the grounds that fatherhood and sonship are not proper converses. The present article shows how a group of twelfth-century philosophers from the milieu around the logician Alberic of Paris handled the problems arising from the use of this illustrative example which they had inherited from their ancient and late-ancient predecessors.
- 17 August 2022
- Published by Walter de Gruyter GmbH in Vivarium
- Vol. 60 (2-3) , 248-270
This Woman Is a Father? The Albricani on a Puzzle about Relations
Medieval philosophers had a predilection for using the correlative pair father and son as an illustrative example in their discussions of relations. The use of this example has sometimes led to charges of confusion on the grounds that fatherhood and sonship are not proper converses. The present article shows how a group of twelfth-century philosophers from the milieu around the logician Alberic of Paris handled the problems arising from the use of this illustrative example which they had inherited from their ancient and late-ancient predecessors.
- 22 July 2020
- Published by Springer Nature
- p. 304-308
Boethius’ De topicis differentiis, Commentaries on
- 22 July 2020
- Published by Springer Nature
- p. 304-308
Boethius’ De topicis differentiis, Commentaries on
- 22 July 2020
- Published by Springer Nature
- p. 340-346
Categories, Commentaries on Aristotle’s
- 5 December 2019
- Published by Springer Nature
- p. 1-6
Categories, Commentaries on Aristotle’s
- 10 January 2018
- Published by Springer Nature
- p. 1-4
Boethius’ De topicis differentiis, Commentaries on
- Open Access
Efficacy of low‐dose topotecan in second‐line treatment for patients with epithelial ovarian carcinoma
BACKGROUND: The high incidence of dose‐limiting myelosuppresion using the U.S. Food and Drug Administration‐approved topotecan dose of 1.5 mg/m2 for 5 days every 3 weeks may have limited its utility in the treatment of patients with epithelial ovarian carcinoma. The objective of the study was to evaluate the treatment results and toxicity of a low‐dose topotecan regimen as second‐line treatment for patients with epithelial ovarian carcinoma.METHODS: A retrospective analysis was conducted of 203 consecutive patients with primary epithelial ovarian carcinoma who were referred to the Finsen Center during the period from June, 1996 to June, 2000. Eligibility criteria included histopathologically documented, International Federation of Gynecology and Obstetrics (FIGO) Stage IC–IV epithelial ovarian carcinoma; first‐line treatment with paclitaxel and a platinum compound; and second‐line treatment with topotecan (1.0 mg/m2 intravenously for 5 days every 3 weeks). Efficacy and toxicity were compared with published results from pivotal trials using the approved dose of topotecan of 1.5 mg/m2 for the same indication.RESULTS: A total of 56 patients received second‐line treatment with the reduced‐dose topotecan regimen because of refractory, persistent, or recurrent disease. In the subgroup of patients with platinum‐resistant and paclitaxel‐resistant disease (n = 43 patients), the response rate of 11.6% (95% confidence interval [95%CI], 3.9–25.1%) was similar to the response rate of 12.4% (95%CI, 6.9–19.9%) in a pivotal trial using standard‐dose topotecan. In patients with platinum‐resistant and paclitaxel‐resistant disease, the median progression free survival and overall survival from the first day of second‐line topotecan treatment were 2.7 months (range, 0.7–19.5 months) and 6.0 months (range, 1.0–32.8 months), respectively. In a multivariate Cox analysis, the initial performance status (0 vs. 1–2; P = 0.040; hazard ratio [HR], 2.05) and the performance status at the time of second‐line treatment (0 vs. 1–2; P < 0.001; HR, 4.50) were identified as independent prognostic factors for overall survival from the start of second‐line treatment. Grade 4 neutropenia was noted in only 5.1% of reduced‐dose topotecan cycles (95%CI, 2.8–8.4%) compared with 33% and 57% of standard‐dose cycles in pivotal studies.CONCLUSIONS: Topotecan at a dose of 1.0 mg/m2 has similar efficacy based on response rate and lower toxicity compared with the approved schedule of 1.5 mg/m2 for 5 days every 3 weeks in second‐line treatment for patients with platinum‐resistant and paclitaxel‐resistant epithelial ovarian carcinoma. However, a comparison of different topotecan doses and schedules preferably should be made in a randomized setting in well‐characterized populations with regard to established prognostic factors. Cancer 2002;95:1656–62. © 2002 American Cancer Society.DOI 10.1002/cncr.10838
Open AccessEfficacy of low‐dose topotecan in second‐line treatment for patients with epithelial ovarian carcinoma
BACKGROUND: The high incidence of dose‐limiting myelosuppresion using the U.S. Food and Drug Administration‐approved topotecan dose of 1.5 mg/m2 for 5 days every 3 weeks may have limited its utility in the treatment of patients with epithelial ovarian carcinoma. The objective of the study was to evaluate the treatment results and toxicity of a low‐dose topotecan regimen as second‐line treatment for patients with epithelial ovarian carcinoma.METHODS: A retrospective analysis was conducted of 203 consecutive patients with primary epithelial ovarian carcinoma who were referred to the Finsen Center during the period from June, 1996 to June, 2000. Eligibility criteria included histopathologically documented, International Federation of Gynecology and Obstetrics (FIGO) Stage IC–IV epithelial ovarian carcinoma; first‐line treatment with paclitaxel and a platinum compound; and second‐line treatment with topotecan (1.0 mg/m2 intravenously for 5 days every 3 weeks). Efficacy and toxicity were compared with published results from pivotal trials using the approved dose of topotecan of 1.5 mg/m2 for the same indication.RESULTS: A total of 56 patients received second‐line treatment with the reduced‐dose topotecan regimen because of refractory, persistent, or recurrent disease. In the subgroup of patients with platinum‐resistant and paclitaxel‐resistant disease (n = 43 patients), the response rate of 11.6% (95% confidence interval [95%CI], 3.9–25.1%) was similar to the response rate of 12.4% (95%CI, 6.9–19.9%) in a pivotal trial using standard‐dose topotecan. In patients with platinum‐resistant and paclitaxel‐resistant disease, the median progression free survival and overall survival from the first day of second‐line topotecan treatment were 2.7 months (range, 0.7–19.5 months) and 6.0 months (range, 1.0–32.8 months), respectively. In a multivariate Cox analysis, the initial performance status (0 vs. 1–2; P = 0.040; hazard ratio [HR], 2.05) and the performance status at the time of second‐line treatment (0 vs. 1–2; P < 0.001; HR, 4.50) were identified as independent prognostic factors for overall survival from the start of second‐line treatment. Grade 4 neutropenia was noted in only 5.1% of reduced‐dose topotecan cycles (95%CI, 2.8–8.4%) compared with 33% and 57% of standard‐dose cycles in pivotal studies.CONCLUSIONS: Topotecan at a dose of 1.0 mg/m2 has similar efficacy based on response rate and lower toxicity compared with the approved schedule of 1.5 mg/m2 for 5 days every 3 weeks in second‐line treatment for patients with platinum‐resistant and paclitaxel‐resistant epithelial ovarian carcinoma. However, a comparison of different topotecan doses and schedules preferably should be made in a randomized setting in well‐characterized populations with regard to established prognostic factors. Cancer 2002;95:1656–62. © 2002 American Cancer Society.DOI 10.1002/cncr.10838
- Open Access
- 1 July 2000
- Published by Elsevier in Annals of Oncology
- Vol. 11 (7) , 829-835
A dose escalating study of topotecan preceding cisplatin in previously untreated patients with small-cell lung cancer
- 1 July 2000
- Published by Elsevier in Annals of Oncology
- Vol. 11 (7) , 829-835
Open AccessA dose escalating study of topotecan preceding cisplatin in previously untreated patients with small-cell lung cancer
- Open Access
- 1 September 1999
- Published by Elsevier in Annals of Oncology
- Vol. 10 (9) , 1043-1050
Paclitaxel, gemcitabine, and cisplatin in non-resectable non-small-cell lung cancer
- 1 September 1999
- Published by Elsevier in Annals of Oncology
- Vol. 10 (9) , 1043-1050
Open AccessPaclitaxel, gemcitabine, and cisplatin in non-resectable non-small-cell lung cancer